Abstract: The present invention relates to a method for predicting a response or resistance to and/or a benefit from treatment with an inhibitor of cyclin-dependent kinases 4 (CDK4/6 inhibitor) in a subject suffering from a neoplastic disease, particularly breast cancer, comprising the step of: determining in a sample obtained from said subject the expression level of at least one marker selected from the group consisting of PD-L1, PIAS2, MAP2K6, DSG3, ABCC12, IFT52, ABCB6, ABCC1, ABCA5, ABCC6, ABCC11, CHUK, SUMO1, TDG, AURKA, SMC3, IKBKG and XPC, wherein the expression level of the at least one marker is indicative for predicting the response or resistance to and/or the benefit from the treatment with the CDK4/6 inhibitor in said subject. The invention further pertains to a CDK4/6 inhibitor for use in the treatment of neoplastic disease, particularly breast cancer, in a subject, wherein the subject has been determined to have a benefit from treatment with a CDK4/6 inhibitor in a method of the invention.

Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.

Abstract: The present invention relates to methods, kits, systems and uses thereof for prediction of the response or resistance to and/or benefit from a cancer immunotherapy of a subject suffering from or being at risk of developing a neoplastic disease, in particular breast cancer, based on the measurement(s) of expression level(s) of at least one marker in samples of said subject. Equally, the present invention relates to methods, kits, systems and uses thereof for predicting the outcome from the cancer immunotherapy treatment in said subject based on the measurement(s) of the expression level(s) of the at least one marker in samples of said subject. Further, the present invention relates to the cancer immunotherapy for use in the treatment of the neoplastic disease, in particular breast cancer, in the subject and to methods for cancer immunotherapy treatment by using the cancer immunotherapy according to the methods of the present invention.

Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Abstract: A brake device for braking a wheel includes a brake drum, a brake pad carrier which is arranged or can be arranged in the brake drum and has at least one brake pad, and an actuator apparatus for the reversible transfer of the brake pad carrier between a braking state, in which the brake pad is operatively connected to the brake drum, and a freewheeling state, in which the operative connection between the brake pad and the brake drum is canceled, the brake pad carrier being elastically deformable for the transfer from the freewheeling state into the braking state.

Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Abstract: A brake device for braking a wheel includes a brake drum, a brake pad carrier which is arranged or can be arranged in the brake drum and has at least one brake pad, and an actuator apparatus for the reversible transfer of the brake pad carrier between a braking state, in which the brake pad is operatively connected to the brake drum, and a freewheeling state, in which the operative connection between the brake pad and the brake drum is canceled, the brake pad carrier being elastically deformable for the transfer from the freewheeling state into the braking state.

Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.

Abstract: Provided herein are methods for predicting a result relating to breast cancer in a patient, the method comprising (a) determining the RNA expression levels of three or more of the following 8 genes in a tumor sample from the patient: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST and MGP; and (b) mathematically combining the expression level values for the genes of the mentioned set to obtain a combined score, the combined score indicating a prognosis for the patient, wherein the RNA expression level values have at least in part not been normalized before the mathematical combination.

Abstract: A wheel includes an outer wheel ring, a hub at least one support device supporting the outer wheel ring on the hub, and an adjustment device configured to adjust the hub relative to the outer wheel ring, wherein the support device has multiple support elements which extend between the hub and the wheel ring, and wherein the support elements are arranged three-dimensionally such that the hub can be adjusted in five degrees of freedom relative to the outer wheel ring.

Abstract: The invention describes how to estimate delta-Cq values from measured (raw-)Cq values gained from PCR measurements and how to calculate confidence intervals for them. This is realized by the following processing steps: A noise model, which might be constructed on some training PCR data, calculates the distribution of the true target material concentration of a single well for an observed measurement results. Said distribution is calculated for all types of measurement results including “Numeric” raw-Cq values as well as Cq being “Undetected”, which denotes that no fluorescence signal was detected during all cycles and thus corresponds to no or very few target molecules.

Abstract: A wheel includes an outer wheel ring, a hub at least one support device supporting the outer wheel ring on the hub, and an adjustment device configured to adjust the hub relative to the outer wheel ring, wherein the support device has multiple support elements which extend between the hub and the wheel ring, and wherein the support elements are arranged three-dimensionally such that the hub can be adjusted in five degrees of freedom relative to the outer wheel ring.

Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.

Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Abstract: A method predicts the residual risk of recurrence after a taxane-free chemotherapy, and the benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent breast cancer. From determination of expression levels of the genes UBE2C, KIF20A, PTGER3, OSBPL1A, CYP27A1, IGKC, in a tumor sample a prognostic score is determined by mathematically combining the expression level values. The prognostic score is compared to thresholds, classifying the patient in three outcome groups. The expression levels of three genes STC1, PCSK6, S100P in the tumor sample are determined, and the expression level values for STC1, PCSK6 and S100P are mathematically combined to yield a predictive combined score, whereas a high predictive combined score generally indicates an increased likelihood of benefit from inclusion of taxane in a chemotherapy regimen in a patient classified to poor and/or intermediate outcome group.

Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.

Abstract: A pool safety fence that includes a plurality of built-in and retractable latch mechanisms, a plurality of mesh fence panels that allows one or more persons to see through either side of the pool safety fence and a plurality of hinges that are attached to the mesh fence panels which allow the pool safety fence to fold-up to be stored. The pool safety fence also includes a plurality of ground stakes that are inserted into a ground surface to secure and stabilize the pool safety fence to the ground surface when in use, a plurality of multi-directional wheels that are disposed underneath each the mesh fence panel to allow the pool safety fence to be easily transferred or positioned and a motor to provide power to move the mesh fence panels into place as desired.